Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
Anne Hamilton(Royal Women's Hospital), Franco M. Muggia(NYU Langone Health), Leonard Liebes(New York University), Nancy M. Kinchla(Dana-Farber Cancer Institute), J. Boyden(National Institutes of Health), Joseph P. Eder(Yale Cancer Center), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Abraham Chachoua(New York University), Anne Zeleniuch‐Jacquotte(New York University), David P. Ryan(East Carolina University), Anne C. Pavlick(Baylor College of Medicine), Jeffrey W. Clark(Massachusetts General Hospital), James R. Wright(Duke University), Julian Adams, H. Yee(National Institutes of Health), Peter J. Elliott(Advanced Process Combinatorics (United States)), Katrina Farrell(National Institutes of Health)
Cited by 100
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Body-Mass Index and Mortality among 1.46 Million White Adults
|New England Journal of Medicine|2010|2.3k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k